Trial reportBlood2017
Enasidenib in mutant
Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915498 (A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation), which is not on this map. Cited by 836 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
836citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Who cites it
836 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Frontiers and hot topics in tumor metabolic reprogramming: a bibliometric analysis from 2014 to 2023.Frontiers in oncology · 2025Pooled it
- Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.Journal of hematology & oncology · 2025Trial
- Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.Blood advances · 2025Trial
- Cost-effectiveness of Enasidenib versus conventional care for older patients withLeukemia & lymphoma · 2025Trial
- Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.Blood advances · 2024Trial
- Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.The Lancet. Oncology · 2024Trial
- HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO).Blood advances · 2026Article
- HMA + venetoclax triplet regimens for the initial treatment of AML in adults.Blood advances · 2026Article
- Current and future therapies for acute myeloblastic leukemia.Journal of hematology & oncology · 2026Review
- Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia.European journal of haematology · 2026Review
- Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.British journal of cancer · 2026Review
- Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.Blood · 2026Article
- Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.Blood cancer discovery · 2026Article
- Two Decades ofCancers · 2026Review
- AI-enabled multi-omics pharmacogenomic modeling guides resistance-aware multitarget optimization of venetoclax therapy in acute myeloid leukemia.NPJ precision oncology · 2026Article
- Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.British journal of haematology · 2026Article
- Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.American journal of hematology · 2026Review
- Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.Science translational medicine · 2026Article
- Pathological Pathways of Olfactory Neuroblastoma: From Molecular Mechanisms to Targeted Therapy: A Narrative Review.Cancers · 2026Review
- Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.Cancer reports (Hoboken, N.J.) · 2026Article
776 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Eytan M SteinMemorial Sloan Kettering Cancer Center, New York, NY.
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Daniel A PollyeaDivision of Hematology, University of Colorado School of Medicine, Aurora, CO.
Amir T FathiMassachusetts General Hospital Cancer Center, Boston, MA.
Gail J RobozWeill Cornell Medical College, New York, NY.
Jessica K AltmanRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Richard M StoneDana-Farber Cancer Institute, Boston, MA.
Daniel J DeAngeloDana-Farber Cancer Institute, Boston, MA.
Ross L LevineMemorial Sloan Kettering Cancer Center, New York, NY.
Ian W FlinnSarah Cannon Research Institute, Nashville, TN.
Hagop M KantarjianThe University of Texas MD Anderson Cancer Center, Houston, TX.
Robert CollinsUniversity of Texas Southwestern Medical Center, Dallas, TX.
Manish R PatelFlorida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL.
Arthur E FrankelUniversity of Texas Southwestern Medical Center, Dallas, TX.
Anthony SteinCity of Hope Comprehensive Cancer Center, Duarte, CA.
Mikkael A SekeresCleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Ronan T SwordsSylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Bruno C MedeirosStanford Comprehensive Cancer Center, Stanford University, Stanford, CA.
Christophe WillekensDépartement d'Hématologie et Département d'Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
Paresh VyasMedical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Alessandra TosoliniCelgene Corporation, Summit, NJ; and.
Qiang XuCelgene Corporation, Summit, NJ; and.
Robert D KnightCelgene Corporation, Summit, NJ; and.
Katharine E YenAgios Pharmaceuticals, Inc., Cambridge, MA.
Sam AgrestaAgios Pharmaceuticals, Inc., Cambridge, MA.
Stephane de BottonDépartement d'Hématologie et Département d'Innovation Thérapeutique, Gustave Roussy, Villejuif, France.
Martin S TallmanMemorial Sloan Kettering Cancer Center, New York, NY.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MMiami Clinical and Translational Science InstituteKL2TR000461 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$2.1MMedical Research Council G1000729Medical Research Council MC_UU_12009/11Medical Research Council MR/L008963/1NCATS NIH HHS KL2 TR000461NCI NIH HHS P30 CA016672
Abstract
Recurrent mutations in isocitrate dehydrogenase 2 (
Indexed as
AdultAgedAged, 80 and overAminopyridinesAntineoplastic AgentsBone MarrowEnzyme InhibitorsFemaleHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMaximum Tolerated DoseMiddle AgedMutationNeoplasm Recurrence, LocalAminopyridinesAntineoplastic AgentsenasidenibEnzyme InhibitorsIDH2 protein, humanIsocitrate DehydrogenaseTriazines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01915498ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.